5/16
08:14 am
tak
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection [Yahoo! Finance]
Low
Report
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection [Yahoo! Finance]
5/14
09:08 am
tak
Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's intent to Expand the Label for its FDA-Approved Liquid Colchicine Pro
Low
Report
Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's intent to Expand the Label for its FDA-Approved Liquid Colchicine Pro
5/14
08:04 am
tak
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting [Yahoo! Finance]
Low
Report
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting [Yahoo! Finance]
5/14
08:00 am
tak
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
Low
Report
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
5/13
06:00 am
tak
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Low
Report
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
5/9
02:21 am
tak
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion [Yahoo! Finance]
Low
Report
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion [Yahoo! Finance]
5/9
02:07 am
tak
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
Low
Report
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
4/30
03:50 am
tak
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion [Yahoo! Finance]
Low
Report
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion [Yahoo! Finance]
4/30
03:50 am
tak
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion [Reuters]
Low
Report
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion [Reuters]
4/26
11:00 am
tak
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround [Yahoo! Finance]
Low
Report
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround [Yahoo! Finance]
4/26
08:41 am
tak
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer [Yahoo! Finance]
Low
Report
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer [Yahoo! Finance]
4/26
08:30 am
tak
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Low
Report
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
4/25
01:40 pm
tak
TAK or CTLT: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Low
Report
TAK or CTLT: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
4/25
11:44 am
tak
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? [Yahoo! Finance]
Low
Report
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? [Yahoo! Finance]
4/25
11:13 am
tak
Atlanta Community Food Bank Opens New Community Food Center in Jonesboro [Yahoo! Finance]
Low
Report
Atlanta Community Food Bank Opens New Community Food Center in Jonesboro [Yahoo! Finance]
4/25
06:39 am
tak
Best Income Stocks to Buy for April 25th [Yahoo! Finance]
Low
Report
Best Income Stocks to Buy for April 25th [Yahoo! Finance]
4/23
02:29 pm
tak
Neurocrine succeeds in mid-stage trial for Takeda-partnered depression drug [Seeking Alpha]
Low
Report
Neurocrine succeeds in mid-stage trial for Takeda-partnered depression drug [Seeking Alpha]
4/22
11:04 am
tak
Antacids Market Size Expected to Reach USD 9.64 Bn by 2032 [Yahoo! Finance]
Low
Report
Antacids Market Size Expected to Reach USD 9.64 Bn by 2032 [Yahoo! Finance]
4/22
04:10 am
tak
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Low
Report
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
4/18
10:10 pm
tak
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch [Yahoo! Finance]
Low
Report
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch [Yahoo! Finance]
4/18
07:08 pm
tak
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease [Yahoo! Finance]
Low
Report
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease [Yahoo! Finance]
4/18
07:00 pm
tak
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Low
Report
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
4/16
01:32 pm
tak
ISPE Announces 2024 Facility of the Year Awards (FOYA) Category Winners [Yahoo! Finance]
Low
Report
ISPE Announces 2024 Facility of the Year Awards (FOYA) Category Winners [Yahoo! Finance]
4/16
01:20 pm
tak
ISPE Announces 2024 Facility of the Year Awards (FOYA) Category Winners
Low
Report
ISPE Announces 2024 Facility of the Year Awards (FOYA) Category Winners
4/15
08:13 am
tak
Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors [Yahoo! Finance]
Low
Report
Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors [Yahoo! Finance]